Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
encompass a spectrum of diseases characterized by an overproduction of
immature blood cells, resulting in a lack of healthy, mature blood
cells in patients.
Unfortunately, the majority of patients with these diseases are not cured with currently available therapies, so MD Anderson’s MDS and AML Moon Shot™ team has committed to developing new treatment options...
September is Ovarian Cancer Awareness Month, an annual time to bring attention to the impact of the disease. This year, more than 22,000 women...
Lung cancer immunotherapy triggers a counterattack by a surface protein found on the tumors of some patients that stifles the immune system...
Almost one year after the Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell therapy for children with acute lymphoblastic leukemia (ALL), researchers at MD Anderson Cancer Center and the Pediatric Acute Lung Injury and Sepsis Investigators Network (PALISI) have published guidelines for managing the treatment in the online issue of Nature Reviews Clinical Oncology. These guidelines outline...
MD Anderson Cancer Center again has been ranked No. 1 for cancer care by U.S. News & World Report’s annual “Best Hospitals” survey...
A well-trained research workforce is essential for addressing both current and future health challenges in the U.S. However, according to...
MD Anderson Cancer Center and Accelerator Life Science Partners, a leading life science investment and management firm, have launched Magnolia...
MD Anderson researchers have uncovered a genetic condition that thwarts the most common immunotherapy used against lung cancer, opening new...
Many are aware of the importance of cancer research for the discovery of new therapies and treatment options, but perhaps less well-known...
A study led by MD Anderson found the investigational drug quizartinib prolongs overall survival for patients with a deadly form of acute myeloid...